Earnings Call Summary | Sarepta Therapeutics(SRPT.US) Q1 2024 Earnings Conference
Earnings Call Summary | Sarepta Therapeutics(SRPT.US) Q1 2024 Earnings Conference
The following is a summary of the Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript:
以下是Sarepta Therapeutics, Inc.（SRPT）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Sarepta reported Q1 net product revenue of $360 million, an increase of about 55% from the same quarter last year.
Revenues from approved therapies contributed to over $334 million since June last year.
The Q1 2024 individual net product sales were respectively $120.2 million for EXONDYS 51, $71.9 million for AMONDYS 45, and $33.5 million for VYONDYS 53.
In Q1 2024, the company recognized $54 million of collaboration and other revenues, a noticeable rise from $2 million in Q1 2023.
The first quarter of 2024 saw a GAAP net income of $36.1 million or $0.38 per basic and $0.37 per diluted share, a considerable improvement over Q1 2023's net loss.
Non-GAAP net income for Q1 2024 was reported at $78.2 million or $0.73 per share, compared to a non-GAAP net loss in Q1 2023.
The company remains well-capitalized with $1.4 billion in cash, cash equivalents, and long-term restricted investments.
Sarepta報告稱，第一季度淨產品收入爲3.6億美元，比去年同期增長約55％。
自去年6月以來，批准療法的收入貢獻了超過3.34億美元。
2024年第一季度，EXONDYS 51的個人淨產品銷售額分別爲1.202億美元，AMONDYS 45的個人淨產品銷售額爲7190萬美元，VYONDYS 53的個人淨產品銷售額分別爲3,350萬美元。
2024年第一季度，該公司確認了5400萬美元的合作和其他收入，較2023年第一季度的200萬美元大幅增長。
2024年第一季度的GAAP淨收益爲3,610萬美元，合每股基本收益0.38美元，攤薄後每股收益0.37美元，比2023年第一季度的淨虧損有了相當大的改善。
2024年第一季度的非公認會計准則淨收益爲7,820萬美元，合每股收益0.73美元，而2023年第一季度的非公認會計准則淨虧損。
該公司仍然擁有充足的資本，擁有14億美元的現金、現金等價物和長期限制性投資。
Business Progress:
業務進展：
Sarepta is gaining access with public and private payers owing to the significant demand from physicians and patients.
The company's BLA supplement for the expansion of ELEVIDYS' labeled population is under FDA review.
Positive progress is noted with ongoing studies for SRP-9001 and SRP-9003.
Advancements in post-marketing studies are being made for golodirsen and casimersen, and a post-marketing commitment for EXONDYS.
There's been significant progress with the launch of ELEVIDYS and the ramp-up of its late-stage clinical trial.
由於醫生和患者的巨大需求，Sarepta正在獲得公共和私人付款人的支持。
該公司用於擴大ELEVIDYS標籤種群的BLA補充劑正在接受美國食品藥品管理局的審查。
正在進行的 SRP-9001 和 SRP-9003 研究取得了積極進展。
golodirsen和casimersen的上市後研究取得了進展，EXONDYS的上市後承諾也取得了進展。
隨着ELEVIDYS的推出及其後期臨床試驗的加強，已經取得了重大進展。
More details: Sarepta Therapeutics IR
更多詳情： Sarepta Therapetics IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。